MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

Core Viewpoint - MaxCyte, Inc. is set to release its financial results for Q4 and full year 2025 on March 24, 2026, after U.S. market close, with a conference call scheduled for 4:30 p.m. Eastern Time to discuss these results [1]. Group 1: Financial Results Announcement - The financial results for the fourth quarter and full year 2025 will be announced after the U.S. market closes on March 24, 2026 [1]. - A conference call will be held at 4:30 p.m. Eastern Time to discuss the financial results [1]. Group 2: Conference Call Details - Investors interested in the conference call must register online, with a recommendation to register at least a day in advance [2]. - A live and archived webcast of the conference call will be available on the MaxCyte website [2]. Group 3: Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3]. - The company utilizes Flow Electroporation technology and SeQure DX gene editing risk assessment services to enable precise and scalable cell engineering [3]. - With over 25 years of experience, MaxCyte aims to shape the future of medicine by empowering researchers globally to develop safe and effective treatments [3].